Microdosing cannabis 2026: what has really been measured and what has not
Microdosing cannabis: what has been measured in studies on sleep, anxiety, and pain, where the provisional EFSA ceiling lies, and what is the legal status in Poland in 2026.
Microdosing cannabis is one of the fastest-growing strategies in cannabinoid phytotherapy. The concept describes taking sub-perceptual amounts, meaning those that do not induce intoxication, yet still modulate the endocannabinoid system (MacCallum i Russo, European Journal of Internal Medicine, 2018). Patients with anxiety, chronic pain, and insomnia are increasingly seeking a gentler alternative to high doses of THC. This article describes the mechanism of action, what has actually been measured in clinical studies, the safety threshold set by EFSA, and the legal status in Poland in 2026. You will not find a ready dosing protocol here, as the literature has not established one, and a separate section explains exactly where this gap comes from.
KEY INFORMATION
- Microdosing involves taking sub-perceptual amounts, meaning below the threshold of intoxication; no numerical definition from a dose-response study has been established (MacCallum and Russo, European Journal of Internal Medicine, 2018).
- The most common goals: anxiety, insomnia, chronic pain, recovery after exertion.
- Odczuwalna stabilizacja efektu wymaga zwykle 2-4 tygodni regularnego stosowania.
- In Poland, CBD is legal without a prescription, while THC requires a prescription for medical marijuana.
- The only number with backing goes the other way: the provisional EFSA ceiling (2026) is 0.0275 mg/kg of body weight per day, about 2 mg for 70 kg.
What is cannabis microdosing and why is it gaining interest?
Microdosing cannabis is the practice of using sub-perceptual amounts of cannabinoids to modulate the endocannabinoid system without inducing a psychoactive effect. The concept itself comes from a practical review of cannabinoid dosing, not from a dose-response study that would numerically define its boundaries (MacCallum i Russo, European Journal of Internal Medicine, 2018). This distinction has practical significance: the review gathers the clinical experience of the authors, not the result of measurement on a group of participants.
Sub-perceptual means below the threshold of conscious perception: a person using such an amount does not feel euphoria or slowed thinking, and effects mainly appear in long-term assessment, for example, as better sleep or a more stable mood. This is why the numbers circulating online as "definition of a microdose" are doubly misleading. First, the perception threshold depends on the individual, the route of administration, and whether they regularly consume cannabinoids. Second, none of these numbers have been derived from a study that compared several dose levels and showed where the effect begins. A table comparing a microdose with a therapeutic dose, which stood in this place, promised precision that the sources do not provide, and has been removed.
Cannabinoids have a nonlinear dose-effect curve, which pharmacologists describe as an "inverted U": after exceeding the optimal range, the effect does not increase but decreases, and side effects typical of higher doses, such as drowsiness or dry mouth, may occur. Therefore, microdosing is not about the maximum amount of substance, but about hitting a narrow therapeutic window.
Interest in this strategy is growing for several reasons at once: concerns about the psychoactive effects of full doses of THC, decreasing acceptance of long-term use of benzodiazepines and opioids for chronic pain, and increasingly better availability of precise forms of administration, such as oils with dropper dispensers or sublingual sprays with a gradation of 1 mg. Microdosing is not a "magic pill" - it requires patience and regularity, and the effect does not appear after an hour, as with a classic painkiller, but gradually accumulates over several weeks.
How does microdosing affect the endocannabinoid system?
The endocannabinoid system (ECS) includes CB1 and CB2 receptors and enzymes responsible for the synthesis and breakdown of endocannabinoids, and its discovery in the 1990s, when anandamide was identified as the first endogenous ligand, opened a new direction in pharmacology (Lu i Mackie, Biological Psychiatry, 2016). Microdosing utilizes the fact that this system responds to minimal concentrations of ligands, not just to full receptor saturation.
| Element ECS | Main location | Rola przy mikrodawce |
|---|---|---|
| Receptor CB1 | brain: cortex, hippocampus, cerebellum | THC activates it gently, without full psychoactivity |
| Receptor CB2 | immune cells, peripheral tissues | involvement in regulating inflammation |
| Anandamid i 2-AG | the whole body | CBD slows the removal of anandamide by competing for FABP transport proteins |
Low-dose THC gently activates CB1, resulting in a slight increase in pain threshold and mild mood stabilization. CBD does not bind directly to CB1 but modulates its activity indirectly and slows the removal of anandamide (Britch i wsp., Psychopharmacology, 2021). Not through the FAAH enzyme: human FAAH does not inhibit cannabidiol, and the increase of anandamide in humans is explained by competition for FABP transport proteins (Elmes, J Biol Chem, 2015). Ben-Shabat and Mechoulam described the “entourage effect” in 1998, which refers to the synergy of cannabinoids and terpenes (European Journal of Pharmacology, 1998), and Russo proposed this synergy in 2011 as a hypothesis to be investigated, not as a conclusion (Russo, British Journal of Pharmacology, 2011). Therefore, microdosing protocols are more often based on broad spectrum or full spectrum oils rather than isolates.
Thus, microdosing often combines THC and CBD in a ratio where CBD clearly dominates, for example, 1:5 or 1:10, while utilizing both central and peripheral signaling.
Anandamide and 2-arachidonoylglycerol (2-AG) are the two main endocannabinoids produced by the body. They are formed and broken down in separate enzymatic pathways, which gives them different physiological roles despite their chemical similarity. A deficiency of these ligands correlates with the clinical endocannabinoid deficiency hypothesis (CECD), described by Russo in 2008 (Neuro Endocrinology Letters, 2008). Microdosing CBD, by extending the half-life of anandamide through competition for FABP transport proteins, could theoretically raise endocannabinoid tone with a lower risk of tolerance than full doses of THC, which flood receptors directly from the outside instead of enhancing signaling already present in the body.
What microdosing protocols for cannabis have scientific support?
None has a study that compares it with another. The names circulating in the literature describe strategies, not verified schemes: the most frequently cited one, “start low, go slow,” comes from a practical review of cannabinoid dosing, based on the collected clinical experience of the authors (MacCallum i Russo, European Journal of Internal Medicine, 2018). The review is not a randomized study and does not determine which scheme works better or from what amount one should start.
The following compilation shows what these names mean and how solid the ground is beneath them. It is not a guideline on which scheme to choose for oneself, as such an answer is not provided by the literature today.
| Daily dose of extract | Na czym polega | State of evidence |
|---|---|---|
| Start low, go slow | the smallest reasonable amount to start, gradual increase | recommendation from a practical review, without comparative study |
| Fixed dose twice a day | established amount in the morning and evening, after finding the threshold | described in clinical practice, not compared with others |
| Schemat cykliczny | kilka dni stosowania, kilka dni przerwy | lack of rigorous studies, the premise is down-regulation of CB1 |
| Przyjmowanie w razie potrzeby (PRN) | only during symptom exacerbation, without a fixed time | lack of studies, can be a transitional stage in establishing a fixed scheme |
The cyclical scheme can be controversial: there is a lack of rigorous clinical studies confirming its superiority over fixed dosing, and some clinicians fear that breaks reduce the continuity of ECS modulation. Supporting breaks is the lower risk of down-regulation of CB1 receptors with regular THC use. The PRN scheme also works as a transitional stage while establishing the optimal fixed protocol.
The common denominator of all these schemes is the same assumption: that there is a narrow window in which the effect appears, and outside of it, it weakens. The assumption seems reasonable and aligns with the shape of the dose-effect curve described above, but no one has measured where this window lies for a specific individual. This is precisely why this text does not provide numbers: regarding the amount and whether it is worth trying at all, one should discuss with a physician knowledgeable about cannabinoid pharmacology, rather than reading it from a table.
What therapeutic benefits do clinical studies document?
The richest evidence base concerns anxiety, insomnia, and chronic pain. Shannon's 2019 study included 72 outpatients with anxiety and sleep disorders: after a month of CBD supplementation, 79.2% reported reduced anxiety, and 66.7% reported improved sleep (Permanente Journal, 2019).
In social anxiety, Bergamaschi's 2011 study showed that a single dose of 600 mg of CBD reduced anxiety induced by a simulated public speaking event to levels comparable to healthy participants (Neuropsychopharmacology, 2011). A later study from the same research group showed that the dose-effect relationship has an inverted U-shape: 57 healthy men received either 150, 300, or 600 mg of cannabidiol before the same public speaking test, and only the middle dose reduced anxiety, as both extremes did not differ from placebo (Linares i wsp., Revista Brasileira de Psiquiatria, 2019). This shows that more does not always mean stronger, even outside the range of microdoses.
In chronic pain, an observational cohort study of 367 patients with fibromyalgia treated with medical marijuana showed a decrease in pain intensity from a median of 9 to 5 on a scale of 0-10, and 81.1% of participants achieved a treatment response (Sagy i wsp., Journal of Clinical Medicine, 2019). A smaller study involving 26 patients with fibromyalgia noted improvements in all domains of the FIQ questionnaire, and half of the participants discontinued other medications used for fibromyalgia (Habib i Artul, Journal of Clinical Rheumatology, 2018). In migraine, a retrospective review of 121 patients showed a decrease in the average frequency of attacks from 10.4 to 4.6 per month after the introduction of medical marijuana (Rhyne i wsp., Pharmacotherapy, 2016).
What do the data say about the impact of microdosing on mood and concentration?
The mechanism of action on anxiety and mood is partially related to the serotonin receptor 5-HT1A, which CBD modulates - this is a different pharmacological target than classic anxiolytics, but the effect can be weaker and requires, as with other indications, several weeks of regular use. Microdosing does not replace pharmacotherapy for clinical depression nor does it have solid confirmation in randomized studies for this indication - it is a supportive tool, not an alternative to treatment conducted by a psychiatrist.
The clinical endocannabinoid deficiency hypothesis, previously described in the context of the mechanism of action, has practical implications specifically in migraine and fibromyalgia: both belong to a group of conditions in which some researchers suspect insufficient baseline endocannabinoid tone as one of the factors. This remains a working hypothesis, not an established mechanism, but it explains why these two indications appear in cannabinoid research more often than other types of chronic pain.
Data on cognitive functions are significantly more limited than in the case of sleep, anxiety, and pain: high doses of THC impair short-term memory, but the impact of microdoses on concentration has yet to receive solid confirmation in controlled studies and is mainly based on survey observations. It is advisable to approach such reports with caution and verify the effect individually by keeping a journal, rather than assuming an improvement in concentration from the outset. Individuals who notice an improvement in focus at low doses should treat this as an individual observation, not a rule confirmed by population studies.
How to choose the form and method of microdosing?
The choice of form depends on dosing precision, speed of action, and convenience. Sublingual oils remain the most frequently recommended form in microdosing protocols precisely because of the ease of accurately differentiating the dose drop by drop.
| Form | Onset of action | Advantage | Wada |
|---|---|---|---|
| Sublingual oil | 15-45 minutes | precision of dose per drop | requires holding under the tongue |
| Capsules | 60-120 minutes | convenience, repeatability of dose | lower bioavailability, slower onset |
| Vaporization | 5-15 minutes | fastest action, good for PRN | difficult milligram precision, equipment needed |
| Food products | 60-120 minutes | long duration of action, convenient for night | risk of uneven cannabinoid distribution in the product |
A standard 10 ml bottle with a 0.05 ml dispenser contains about 200 drops, and the amount of cannabidiol per drop is directly derived from the concentration and is stated on the product label. This is arithmetic of the product, not a guideline regarding quantity: the volume of a drop depends on the calibration of the pipette and the density of the carrier, so two pipettes can differ by several dozen percent. Forms also clearly differ in bioavailability: sublingual oil held under the tongue for 60-90 seconds usually achieves the highest bioavailability among oral forms, capsules lose some substance during the first pass through the liver, and vaporization has the highest bioavailability of all forms, at the cost of more difficult dosing precision.
When choosing a form, it is worth checking the certificate of analysis (COA), as a product without it may have a concentration that deviates from what is declared on the label, making precise microdosing difficult regardless of how carefully drops or milligrams are counted. This is especially true for gummies and other food products: with uneven cannabinoid distribution in the product mass, one piece from the same package may contain a noticeably different dose than another, so for microdosing, products with a confirmed dose per piece are better suited, not just collectively per package.
What does the safety and tolerance of microdosing look like?
In 2026, EFSA set a provisional safe dose of CBD at 0.0275 mg per kilogram of body weight per day, which is about 2 mg for a 70 kg person, and this is only for products with a purity of at least 98%. The amounts described in practice as microdoses are around this value or exceed it, so it is not a margin that can be overlooked. This is the only number in this article related to body weight, and it is a limit, not a point from which anything starts to work.
The most common side effects of CBD microdosing are dry mouth, mild drowsiness, and, at higher doses, diarrhea. For THC microdoses, light dizziness and increased appetite are added. Tolerance to THC develops with regular use over several weeks, which is why some schemes introduce periodic tolerance breaks, meaning a few days without THC to reset the sensitivity of CB1 receptors - a similar mechanism to what was previously described in the cyclic scheme.
CBD affects cytochrome P450 enzymes, including CYP3A4, which can alter the metabolism of concurrently taken medications, such as some anticoagulants, antiepileptics, or immunosuppressants (Brown and Winterstein, Journal of Clinical Medicine, 2019). The risk increases with drugs that have a narrow therapeutic window, meaning those where the difference between an effective and harmful dose is small - even a moderate change in drug concentration in the blood can have clinical significance, which is why consulting a doctor or pharmacist before starting microdosing is not a formality, but a real element of therapy safety.
Absolute contraindications for THC microdosing include pregnancy, breastfeeding, active psychosis or schizophrenia, and age under 18. Relative contraindications include a family history of psychosis and severe depression with suicidal thoughts. CBD has significantly fewer contraindications, mainly severe liver diseases and possible drug interactions. Individuals with unstable coronary artery disease should exercise caution, as microdoses of THC can temporarily raise heart rate, which is usually harmless in a healthy person, but requires consultation before starting therapy in the case of unstable heart disease.
What is the difference between CBD microdosing and THC microdosing?
CBD microdosing and THC microdosing are two different tools with distinct legal and pharmacological profiles. CBD does not require a prescription in Poland, while THC does - the number of prescriptions for medical marijuana is increasing year by year: in 2023, about 313,000 such prescriptions were issued in Poland, and in the first quarter of 2024, another 115,000, compared to just 11,400 filled in 2020.
CBD serves as the first line of microdosing: no psychoactive effects, no legal restrictions, good safety profile. It is a good option for individuals sensitive to psychotropic medications, professional drivers, or athletes, for whom any uncertainty regarding psychomotor state is a concern. If after 4-8 weeks the effect of CBD alone is satisfactory, adding THC is usually unnecessary - many patients remain on just CBD for years.
THC is mainly added when chronic pain, severe insomnia, or neuropathy do not respond adequately to CBD alone, as THC modulates pain perception at the central level in a way that CBD does not provide on its own. In Poland, adding THC requires a prescription and a visit to the doctor overseeing medical marijuana therapy, available mainly as dried flower or oil by prescription in pharmacies that conduct such transactions, where the doctor, together with the patient, selects a strain with the appropriate THC to CBD ratio.
The ratios described in practice are 1:1 (equal amounts of THC and CBD, stronger effect on pain, but clearer risk of subtle psychoactivity) and variants from 1:5 to 1:20 with a dominance of CBD, where THC mainly acts as an enhancer of the entourage effect. The only reference point with official status is the characteristics of Sativex, a registered drug for spasticity in multiple sclerosis: a ratio of 1:1 and about 2.7 mg of THC and 2.5 mg of CBD per spray. This is information about a medicinal product, the dosing of which is determined by a doctor, and not a starting point for personal calculations.
Why won't you find a ready-made dosing protocol here?
Because there is nothing to base it on. A fixed schedule with a breakdown by weeks and a number of milligrams to start was removed because no study has established these numbers. It looked precise, but the precision came from the format of the table, not from measurement.
This is best seen when comparing the numbers that were actually measured. Shannon administered cannabidiol to 72 outpatient patients for a month and noted an improvement in sleep in two-thirds of them. Linares compared single doses of 150, 300, and 600 mg in 57 healthy men. Sativex, the only registered drug in this comparison, contains 2.7 mg of THC per spray. EFSA's provisional ceiling for a supplement is about 2 mg of cannabidiol per day for a 70 kg person. These values differ by several dozen times and come from completely different situations: from a supervised clinical trial, from therapy with a prescription drug, and from daily intake of a product from a store. One schedule cannot be constructed from them.
What remains makes sense regardless of the numbers. The first step is a consultation with a doctor knowledgeable about cannabinoid pharmacology, especially important in chronic diseases, polypharmacy, and psychiatric conditions in the history. The second step is choosing a product: for CBD, a good broad-spectrum oil with a certificate of analysis (COA), for THC, a prescription. The third step is a journal of intake and well-being, as subtle changes are only visible when comparing weeks, not days.
In microdosing, it is easy to confuse the lack of immediate effect with a lack of effectiveness. Microdoses act like a course correction, not an emergency brake: after a few weeks, a patient rarely says they felt a sudden change; they more often notice that they have been sleeping better or feeling less anxious for some time, unable to pinpoint the exact moment of improvement. This is a typical signal that the endocannabinoid system is stabilizing, not evidence of a lack of action.
What is the legal status of microdosing hemp in Poland in 2026?
In Poland, industrial hemp, in which the sum of delta-9-THC and tetrahydrocannabinolic acid (THCA) does not exceed 0.3% when calculated on a dry mass basis, is a legal source of CBD, available without a prescription (Article 4 point 5 of the Act of July 29, 2005, on counteracting drug addiction, Journal of Laws 2005 No. 179 item 1485, as amended by the Act of March 24, 2022, Dz.U. 2022 poz. 763). The threshold is counted as the sum of both compounds, not just delta-9-THC, which is important when interpreting laboratory test results. Therefore, microdosing of CBD alone is fully legal for adults, and the Polish CBD market is worth about 130 million euros (Fakty Konopne, 2024).
Microdosing THC requires a prescription and medical marijuana. The Act of July 7, 2017, allowed the use of cannabis as a pharmaceutical raw material in Poland (Dz.U. 2017 poz. 1458), and any doctor can issue a prescription without separate authorization. The amendment to the Act on counteracting drug addiction, which comes into force on August 27, 2026, does not change the THC threshold, the classification of substances, or the principles of retail sale of hemp products - it pertains to substitution treatment and laboratory reporting, so the legal status described here remains valid even after this date.
- It is allowed: to purchase, possess, and use CBD products in stores and pharmacies, as well as to buy medical marijuana with a prescription in pharmacies that conduct sales.
- It is not allowed: to drive under the influence of THC regardless of the dose - tests can detect THC even after a microdose for 24-72 hours after consumption, while CBD is not detected as a drug.
- It is not allowed: to import medical marijuana for personal use without a prescription issued in Poland, nor to share it with others, even family members, even if the prescription itself is valid.
- It is not allowed: to grow cannabis for medical purposes on your own - having a valid prescription for medical marijuana does not change this prohibition.
In sports, WADA removed CBD from the list of prohibited substances back in 2018, so microdosing CBD is safe for professional athletes, even during competition periods. THC remains on the list of prohibited substances during competition periods, so patients taking microdoses should exercise caution during competitions and doping tests. For amateurs engaging in recreational sports, there are no formal restrictions.
What mistakes and pitfalls most often spoil the effect of microdosing?
Microdosing requires discipline and patience, which many patients lack in the first weeks. The absence of immediate effects is often the most common reason people abandon the protocol before it has a chance to work - some individuals give up on microdosing within the first weeks, before the modulation of the endocannabinoid system has a chance to stabilize noticeably.
| Error | Dlaczego szkodzi | How to avoid |
|---|---|---|
| Increasing the dose too quickly | skipping the narrow therapeutic window | any change in dosage should be agreed upon with the attending physician |
| Brak dziennika | subtle improvements are hard to assess from memory | notowanie dawki, godziny i samopoczucia codziennie |
| Irregular use | ECS responds to consistent, repeatable doses | a constant alarm or reminder for dosing time |
| Poor product choice | concentration without COA may not match the label | produkt z aktualnym certyfikatem analizy |
| Combining with alcohol | may unpredictably enhance the effects of THC | avoiding combinations, consulting when on regular medications |
The common denominator of most of these mistakes is the expectation of effects within hours, as with a classic medication. Microdosing works differently: comparing the first week to the fourth usually shows a clear difference that is not visible day by day.
What trends in microdosing are emerging in 2026?
Three trends dominate current research on cannabinoids. The first is the development of nanoemulsions and liposomal forms, which break down oil into much smaller droplets, thereby increasing oral bioavailability compared to regular sublingual oil - in Poland, such products are still rare, but the first premium items are starting to appear on the market. In practice, this would mean that the same microdose works more effectively or that the dose can be reduced while maintaining the effect.
The second trend is research on polymorphisms of enzymes that metabolize cannabinoids, such as CYP2C9 and FAAH, which could in the future allow for dose selection tailored to the individual metabolism of the patient instead of one universal recommendation - individuals with slower metabolism may achieve higher concentrations of cannabinoids in the blood at the same nominal dose than those with faster metabolism. These studies are still experimental, but they indicate a direction towards more precise cannabinoid phytotherapy.
The third trend is the growing interest in the "low-dose" and "wellness" segment in the global medical marijuana market, which according to Grand View Research was worth about $21 billion in 2023, with a growth forecast to $102.2 billion by 2030 at an average annual growth rate of 25.4% (Grand View Research, 2024). This shows that microdosing is ceasing to be a niche practice and is increasingly entering the mainstream of cannabinoid phytotherapy.
Is microdosing cannabis a good choice for you?
Microdosing cannabis is a strategy with partial support in research, requiring patience and discipline. Sub-perceptual amounts are intended to modulate the endocannabinoid system without intoxicating effects, and the studies cited in this article document the potential of cannabinoids in anxiety, insomnia, chronic pain, and migraines. However, none of them have established how much a specific person should take.
In Poland, microdosing CBD alone is fully legal and available without a prescription. Microdosing THC requires a prescription and medical marijuana available in pharmacies conducting sales. The most important factors remain: consultation with a physician, choosing a verified product with a certificate of analysis, keeping a journal, and patience for at least 4-8 weeks before drawing conclusions about effectiveness.
Not everyone will benefit from microdosing, but for many, it is a gentler alternative or complement to classic therapies. The most sensible starting point is broad spectrum oil with a current certificate of analysis, and the amount should be determined with a physician, not a ready and rigid number of milligrams prescribed in advance to everyone.
Remember to have realistic expectations: microdosing is not a "magic pill" but a tool for subtle, gradual modulation of the endocannabinoid system. If you are starting, keep a journal and consult with a specialist knowledgeable in cannabinoid pharmacology before changing anything in your regimen - this is one decision that best protects against accidentally skipping the narrow therapeutic window.
Frequently Asked Questions
What is microdosing hemp?
This involves taking sub-perceptual amounts of cannabinoids, meaning those that do not produce a psychoactive effect. The concept comes from a practical review of cannabinoid dosing, not from a dose-response study, so its boundaries have not been numerically defined (MacCallum i Russo, European Journal of Internal Medicine, 2018). The goal is to modulate the endocannabinoid system without intoxication.
Is microdosing CBD alone legal in Poland in 2026?
Yes. Hemp, in which the total delta-9-THC and THCA does not exceed 0.3% of dry mass, is a legal source of CBD (Article 4, point 5 of the Act on Counteracting Drug Addiction, Dz.U. 2022 poz. 763). Microdosing THC requires a prescription and medical marijuana prescribed by a doctor. The Polish CBD market is worth about 130 million euros (Fakty Konopne, 2024).
How quickly can effects of cannabis microdosing be seen?
Sublingual forms take effect after 15-45 minutes, capsules and edibles after 60-120 minutes, and vaporization after 5-15 minutes. A noticeable stabilization of effects usually requires 2-4 weeks of regular use (MacCallum i Russo, European Journal of Internal Medicine, 2018). Subtle effects appear gradually, not suddenly.
Does microdosing cause tolerance or addiction?
At sub-perceptual doses, the risk is significantly lower than with classic dosing. In 2026, EFSA set a provisional safe dose for CBD at 0.0275 mg per kilogram of body weight per day, which is about 2 mg for a 70 kg person, and noted that for individuals under 25, pregnant and breastfeeding women, and those taking medications, safety cannot be determined. Tolerance to THC, however, develops with regular use over several weeks.
What do studies say about microdosing for insomnia?
The most frequently cited work is Shannon's study from 2019: 72 outpatients with anxiety and sleep disorders took cannabidiol for a month, and 66.7% of them reported improved sleep (Permanente Journal, 2019). This was not a randomized trial and did not establish a dosing regimen. The effect builds up gradually over 2-4 weeks.
Does microdosing affect the ability to drive?
Sub-perceptual doses of CBD do not impair psychomotor functions and are not detected as drugs in tests. THC can be detectable in drug tests for another 24-72 hours after consumption, even after very small amounts. In Poland, driving under the influence of THC is punishable regardless of the dose.
Can cannabis microdosing be combined with medications?
With caution. CBD affects cytochrome P450 enzymes, including CYP3A4, which can alter the metabolism of many concurrently taken medications (Brown and Winterstein, Journal of Clinical Medicine, 2019). Consultation with a doctor or pharmacist is essential, especially with drugs that have a narrow therapeutic window.
After what time is the effectiveness of the microdosing protocol assessed?
A minimum of 2-4 weeks of regular use allows for an initial assessment of effects on sleep, anxiety, and pain. A more comprehensive assessment of symptoms is usually observed after 6-8 weeks (Shannon i wsp., Permanente Journal, 2019). Keeping a journal of doses and well-being facilitates an objective evaluation of the protocol.
You can read more about the method itself and who it actually works for in the text Microdosing CBD and THC: a trend or an effective method, and if you are wondering how much of the effect of microdoses is real action and how much is placebo, check Microdosing vs. placebo - what controlled studies really say. For those who are just looking for their optimal dose, the text may also help Dr Dustin Sulak o dawkowaniu CBD, and with regular use of THC, it is worth knowing the signals described in Tolerance break - how to lower tolerance to THC/CBD. Sublingual oils used in most of the protocols described here can be found in the category oils.
This article is for informational and educational purposes and does not constitute medical advice. Cannabis microdosing, especially involving THC, requires consultation with a doctor knowledgeable about cannabinoid pharmacology. Before starting to use cannabis or CBD for therapeutic purposes, consult with a doctor, especially if you are taking other medications, are pregnant, breastfeeding, or have psychiatric conditions in history. THC microdosing in Poland is only possible based on a prescription for medical marijuana.
Author: Michał Waluk · Opublikowano: 2026-05-11 · Aktualizacja: 2026-08-17
